产品展示
Anti-phospho-CBL2(Tyr731)磷酸化原癌蛋白CBL2抗体
点击次数：208发布时间：2012/12/26 8:52:41
更新日期：2024/9/5 14:43:40
所 在 地：其它
产品型号：BY-3089R
优质供应
详细内容
货号：BY-3089R
英文名称：Anti-phospho-CBL2（Tyr731）
中文名称：磷酸化原癌蛋白CBL2抗体
其他名称：C CBL; Cas-Br-M （murine） ecotropic retroviral transforming sequence; Casitas B lineage lymphoma proto oncogene; CBL 2;E3 ubiquitin protein ligase CBL; Oncogene CBL2; Proto oncogene c CBL; RGD1561386; RING finger protein 55; RNF55v Signal transduction protein CBL; 4732447J05Rik;
抗体来源：Rabbit
克隆类型：polyclonal
蛋白分子量：predicted molecular weight: 55kDa
纯化方法：affinity purified by Protein A
交叉反应：hu, rat, mo
产品介绍：The proto oncogene c CBL was initially identified as the cellular homologue of v CBL oncogene that induces pre B cell lymphomas ａnd myeloid leukemias in mice. In more recent studies CBL has been shown to be a negative regulator of tyrosine kinase signaling. The ubiquitin ligase activity of CBL leads to the degradation of tyrosine kinases, thus attenuating the signal of receptors. Targets of CBL include activated protein tyrosine kinases belonging to the Src ａnd Syk/Zap 70 families. An additional mechanism to attenuate receptor signaling is thought to be achieved by CBL’s interaction with downstream targets of tyrosine kinases, such as PI 3K ａnd Vav. CBL2（Casitas B-lineage lymphoma）是一类广泛分布的细胞内蛋白,属于泛素连接酶E3, Cbl参与细胞内信号转导的负向调控,这对于维持细胞的内稳态具有重要作用。Cbl突变后可成为癌蛋白;许多肿瘤细胞则表现为与增殖有关的分子（如受体型蛋白酪氨酸激酶,RTK）因发生突变或其它遗传学改变不受Cbl负调控。加强或重建Cbl的负调控作用,或许能够从受体活化的上游信号开始抑制肿瘤细胞增殖。为利用Cbl的泛素连接酶活性,并使其能够特异性地降解某些信号转导分子,从而对一些与肿瘤生长有关的细胞增殖进行负向调节.
